The strategic move initiated by Bracco in February 2023 dealt a significant blow to management, impacting their expansion plans in the US pharmaceutical market. By altering existing laws to mandate all contrast drugs, Bracco aimed to impede Voyageur's market entry. Instead of resorting to generic drug manufacturing, Voyageur opted to develop novel and enhanced pharmaceuticals tailored specifically for the lucrative US market. This strategic shift reflects a savvy decision because it enhances their intellectual property (IP) protection, thereby increasing the intrinsic value of their products versus generics. Consequently, Voyageur is now poised to challenge Bracco's market dominance effectively. In a sense, this strategy backfired for Bracco. Voy will be submitting using the 505(2)(b) system, which is fast and they will begin doing all their trial data when they start human testing.
Transitioning into a pharmaceutical company in 2020, Voyageur is on track compared to traditional pharma startups, typically constrained by a plus 5-year timeframe to bring products to market. Remarkably, within just 18 months, they successfully introduced five new drugs—this was no easy task, considering cash constraints, I am curious how they did this as it usually costs millions of dollars to create just one drug. The regulatory process is very costly and time consuming. If they replicate this speed and success with their fullerene line, it will indeed signify a remarkable achievement.
Critics of Voyageur's management, lacking industry experience, fail to appreciate the company's strategic vision and rapid progress. The stagnant nature of stock trading on the venture exchange underscores the need to leave the tsx-v, a sinking ship of zero value, and shows new entrepreneurs that going public is not a route to go to start a company, in fact it is a complete waste of money.
Challenge to the nay sayers, find a company with 5 new drugs with HC approval moving toward FDA, and multiple new fullerene drugs (or any drugs 3 plus) in the pipeline, and tell me what exchange they are on and their market cap? We need to demand management list this company on an exchange that will trade pharma stocks with multiples on valuation. NASDAQ? Then dilution is irrelevant. The drug development side of this company will be extremely significant.